Pushing the Boundaries of Knowledge in Alpha-1 Antitrypsin Deficiency.

Authors

José María Hernández-Pérez, Silvia Castillo-Corullón, Ilaria Ferrarotti, Beatriz Martínez-Delgado, Francisco Casas-Maldonado, Francisco José Dasí-Fernández

Published in

Archivos de bronconeumologia. Oct 01, 2026. Epub Oct 01, 2026.

Abstract

Alpha-1 antitrypsin deficiency (AATD) is a rare inherited disorder caused by mutations in the SERPINA1 gene. AATD is one of the leading causes of emphysema in young adults and of liver cirrhosis in children and adults. Despite significant underdiagnosis and high clinical variability, recent research is rapidly transforming the field. Advances in molecular biology and translational medicine have identified new biomarkers and therapeutic targets, although reliable predictors of disease progression remain limited. While augmentation therapy is the only approved pharmacological option for pulmonary involvement and no specific treatment exists for liver disease, innovative strategies are remodeling the therapeutic landscape. Gene therapy, RNA interference, gene editing, and epigenetic modulation are showing promising preclinical and early clinical results, aiming to correct the underlying defect rather than manage symptoms. This review focuses on these emerging advances, highlighting cutting-edge preclinical and translational developments with potential to redefine AATD management and move toward curative approaches.

PMID:
42823318
Bibliographic data and abstract were imported from PubMed on 02 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.